| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastritis | 106 | 2024 | 371 | 20.330 |
Why?
|
| Helicobacter Infections | 167 | 2024 | 1263 | 16.270 |
Why?
|
| Helicobacter pylori | 161 | 2024 | 1320 | 13.950 |
Why?
|
| Gastric Mucosa | 93 | 2024 | 485 | 10.910 |
Why?
|
| Stomach Neoplasms | 69 | 2024 | 540 | 10.140 |
Why?
|
| Celiac Disease | 16 | 2023 | 68 | 6.790 |
Why?
|
| Gastritis, Atrophic | 27 | 2024 | 60 | 6.750 |
Why?
|
| Colitis, Microscopic | 11 | 2023 | 15 | 6.680 |
Why?
|
| Eosinophilic Esophagitis | 23 | 2022 | 75 | 6.380 |
Why?
|
| Inflammatory Bowel Diseases | 15 | 2023 | 314 | 6.350 |
Why?
|
| Precancerous Conditions | 26 | 2023 | 283 | 5.880 |
Why?
|
| Enteritis | 17 | 2024 | 54 | 5.400 |
Why?
|
| Biopsy | 97 | 2023 | 1236 | 5.320 |
Why?
|
| Eosinophilia | 20 | 2024 | 101 | 4.460 |
Why?
|
| Stomach | 36 | 2022 | 273 | 4.400 |
Why?
|
| Adenoma | 14 | 2022 | 135 | 4.270 |
Why?
|
| Duodenitis | 9 | 2024 | 14 | 4.260 |
Why?
|
| Colonic Polyps | 10 | 2022 | 81 | 3.990 |
Why?
|
| Gastroesophageal Reflux | 21 | 2024 | 294 | 3.820 |
Why?
|
| Polyps | 10 | 2020 | 45 | 3.460 |
Why?
|
| Metaplasia | 41 | 2023 | 215 | 3.230 |
Why?
|
| Adenocarcinoma | 26 | 2022 | 998 | 2.900 |
Why?
|
| Colonic Neoplasms | 9 | 2022 | 247 | 2.730 |
Why?
|
| Prevalence | 46 | 2024 | 2433 | 2.530 |
Why?
|
| Intestinal Mucosa | 24 | 2018 | 776 | 2.440 |
Why?
|
| Humans | 366 | 2024 | 124409 | 2.380 |
Why?
|
| Esophagitis | 9 | 2023 | 40 | 2.380 |
Why?
|
| Duodenum | 17 | 2023 | 98 | 2.310 |
Why?
|
| Eosinophils | 18 | 2024 | 121 | 2.280 |
Why?
|
| Esophagus | 14 | 2023 | 215 | 2.260 |
Why?
|
| Middle Aged | 150 | 2024 | 26461 | 2.210 |
Why?
|
| Aged | 112 | 2024 | 19481 | 2.080 |
Why?
|
| Colonoscopy | 16 | 2022 | 240 | 2.060 |
Why?
|
| Crohn Disease | 8 | 2023 | 283 | 2.050 |
Why?
|
| Colitis, Collagenous | 3 | 2022 | 3 | 1.990 |
Why?
|
| Barrett Esophagus | 14 | 2020 | 339 | 1.980 |
Why?
|
| Adult | 149 | 2024 | 29398 | 1.940 |
Why?
|
| Case-Control Studies | 32 | 2023 | 3268 | 1.910 |
Why?
|
| Male | 194 | 2024 | 61033 | 1.820 |
Why?
|
| Aged, 80 and over | 53 | 2021 | 6471 | 1.760 |
Why?
|
| Endoscopy, Digestive System | 12 | 2020 | 153 | 1.700 |
Why?
|
| Endoscopy, Gastrointestinal | 19 | 2022 | 243 | 1.680 |
Why?
|
| Strongyloidiasis | 28 | 1996 | 43 | 1.650 |
Why?
|
| Female | 162 | 2024 | 66307 | 1.620 |
Why?
|
| Stomach Diseases | 8 | 2015 | 56 | 1.510 |
Why?
|
| Colorectal Neoplasms | 8 | 2022 | 566 | 1.460 |
Why?
|
| Pathology | 5 | 2016 | 39 | 1.400 |
Why?
|
| Granuloma | 3 | 2024 | 68 | 1.390 |
Why?
|
| Young Adult | 43 | 2024 | 8979 | 1.370 |
Why?
|
| Gastrointestinal Diseases | 9 | 2024 | 333 | 1.350 |
Why?
|
| Databases, Factual | 15 | 2021 | 1174 | 1.340 |
Why?
|
| Proton Pump Inhibitors | 10 | 2019 | 261 | 1.340 |
Why?
|
| Guideline Adherence | 5 | 2017 | 377 | 1.260 |
Why?
|
| Colitis, Lymphocytic | 2 | 2022 | 2 | 1.250 |
Why?
|
| Staining and Labeling | 8 | 2018 | 187 | 1.200 |
Why?
|
| Cardia | 6 | 2010 | 27 | 1.150 |
Why?
|
| United States | 41 | 2021 | 10775 | 1.130 |
Why?
|
| Cross-Sectional Studies | 19 | 2022 | 3427 | 1.130 |
Why?
|
| Colon | 6 | 2015 | 353 | 1.120 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 11 | 2013 | 61 | 1.100 |
Why?
|
| Adolescent | 45 | 2024 | 19360 | 1.060 |
Why?
|
| Pathology, Clinical | 4 | 2016 | 23 | 1.040 |
Why?
|
| Esophagogastric Junction | 5 | 2024 | 28 | 1.030 |
Why?
|
| Gastrointestinal Neoplasms | 5 | 2010 | 79 | 1.020 |
Why?
|
| Odds Ratio | 15 | 2021 | 1246 | 1.020 |
Why?
|
| Gastrointestinal Tract | 6 | 2024 | 215 | 1.010 |
Why?
|
| Immunohistochemistry | 20 | 2019 | 1684 | 1.000 |
Why?
|
| Atrophy | 21 | 2022 | 236 | 1.000 |
Why?
|
| Lymphocytosis | 2 | 2019 | 14 | 0.980 |
Why?
|
| Risk Factors | 34 | 2024 | 10150 | 0.980 |
Why?
|
| Intestines | 15 | 2015 | 573 | 0.980 |
Why?
|
| Age Distribution | 11 | 2021 | 413 | 0.940 |
Why?
|
| Gastric Acid | 4 | 2019 | 50 | 0.930 |
Why?
|
| Colitis, Ulcerative | 5 | 2023 | 208 | 0.920 |
Why?
|
| Duodenal Neoplasms | 3 | 2014 | 21 | 0.910 |
Why?
|
| Duodenal Ulcer | 18 | 2020 | 127 | 0.880 |
Why?
|
| Anti-Ulcer Agents | 14 | 2003 | 111 | 0.870 |
Why?
|
| Peptic Ulcer | 14 | 2020 | 147 | 0.860 |
Why?
|
| Child | 39 | 2022 | 24528 | 0.820 |
Why?
|
| Pyloric Antrum | 18 | 2007 | 64 | 0.820 |
Why?
|
| Duodenal Diseases | 3 | 2017 | 34 | 0.810 |
Why?
|
| Intestinal Neoplasms | 4 | 2019 | 39 | 0.810 |
Why?
|
| Esophageal Mucosa | 2 | 2024 | 11 | 0.810 |
Why?
|
| Histocytochemistry | 7 | 2016 | 99 | 0.790 |
Why?
|
| Gastroenterology | 5 | 2017 | 191 | 0.790 |
Why?
|
| Colitis | 8 | 2018 | 154 | 0.780 |
Why?
|
| Strongyloides | 15 | 1989 | 16 | 0.770 |
Why?
|
| Helicobacter | 4 | 2018 | 17 | 0.750 |
Why?
|
| Esophageal Neoplasms | 6 | 2016 | 359 | 0.740 |
Why?
|
| Adenomatous Polyps | 2 | 2020 | 13 | 0.710 |
Why?
|
| Famous Persons | 3 | 2016 | 15 | 0.670 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2019 | 10 | 0.670 |
Why?
|
| Child, Preschool | 24 | 2020 | 14086 | 0.660 |
Why?
|
| Infant | 21 | 2020 | 12480 | 0.640 |
Why?
|
| Carcinoid Tumor | 2 | 2013 | 25 | 0.630 |
Why?
|
| Terminology as Topic | 8 | 2015 | 225 | 0.620 |
Why?
|
| Colonic Diseases | 2 | 2017 | 38 | 0.620 |
Why?
|
| Sex Distribution | 6 | 2021 | 297 | 0.620 |
Why?
|
| Mast Cells | 5 | 2024 | 74 | 0.620 |
Why?
|
| Logistic Models | 8 | 2018 | 1804 | 0.600 |
Why?
|
| Esophagitis, Peptic | 4 | 2016 | 33 | 0.600 |
Why?
|
| Alcian Blue | 1 | 2018 | 3 | 0.600 |
Why?
|
| Periodic Acid | 1 | 2018 | 7 | 0.600 |
Why?
|
| Mucositis | 1 | 2018 | 18 | 0.590 |
Why?
|
| Predictive Value of Tests | 15 | 2018 | 2122 | 0.590 |
Why?
|
| Stomach Ulcer | 11 | 2020 | 92 | 0.590 |
Why?
|
| Chronic Disease | 17 | 2022 | 1186 | 0.580 |
Why?
|
| Diarrhea | 4 | 2015 | 316 | 0.570 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 73 | 0.540 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 10 | 0.540 |
Why?
|
| Hyperplasia | 8 | 2022 | 209 | 0.520 |
Why?
|
| Retrospective Studies | 26 | 2023 | 16232 | 0.510 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 872 | 0.510 |
Why?
|
| Prognosis | 13 | 2018 | 4553 | 0.510 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 17 | 0.510 |
Why?
|
| Anti-Bacterial Agents | 16 | 2021 | 2416 | 0.500 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 1417 | 0.490 |
Why?
|
| Epithelioid Cells | 1 | 2014 | 11 | 0.480 |
Why?
|
| Parietal Cells, Gastric | 2 | 2022 | 38 | 0.480 |
Why?
|
| Follow-Up Studies | 16 | 2022 | 5107 | 0.470 |
Why?
|
| Ileal Diseases | 2 | 2010 | 21 | 0.460 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 1218 | 0.460 |
Why?
|
| Omeprazole | 12 | 2019 | 98 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 1264 | 0.450 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 53 | 0.450 |
Why?
|
| Medical Errors | 2 | 2006 | 155 | 0.450 |
Why?
|
| Intestine, Small | 5 | 2013 | 313 | 0.450 |
Why?
|
| Choristoma | 2 | 2012 | 49 | 0.440 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 97 | 0.440 |
Why?
|
| Prospective Studies | 15 | 2024 | 6089 | 0.440 |
Why?
|
| Immunoglobulin G | 18 | 2009 | 772 | 0.440 |
Why?
|
| Sex Factors | 7 | 2017 | 1267 | 0.430 |
Why?
|
| Gastrectomy | 2 | 2012 | 90 | 0.430 |
Why?
|
| Gastrins | 5 | 2008 | 33 | 0.430 |
Why?
|
| Antigens, Bacterial | 8 | 2004 | 313 | 0.430 |
Why?
|
| Neuroendocrine Cells | 1 | 2013 | 9 | 0.430 |
Why?
|
| Diagnosis, Differential | 9 | 2014 | 1892 | 0.410 |
Why?
|
| Severity of Illness Index | 13 | 2022 | 2896 | 0.410 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 42 | 0.410 |
Why?
|
| Registries | 2 | 2018 | 1410 | 0.400 |
Why?
|
| Risk Assessment | 8 | 2024 | 3382 | 0.400 |
Why?
|
| Gastroparesis | 1 | 2013 | 66 | 0.400 |
Why?
|
| Biomedical Research | 2 | 2017 | 518 | 0.390 |
Why?
|
| Antibodies, Bacterial | 6 | 2009 | 386 | 0.380 |
Why?
|
| Leukocyte Count | 9 | 2020 | 247 | 0.380 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1695 | 0.380 |
Why?
|
| Lymphocytes | 3 | 2016 | 406 | 0.380 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 628 | 0.370 |
Why?
|
| Arsenic Poisoning | 1 | 2011 | 5 | 0.370 |
Why?
|
| Age Factors | 6 | 2017 | 2805 | 0.360 |
Why?
|
| Disease Management | 2 | 2020 | 519 | 0.360 |
Why?
|
| Autoantibodies | 2 | 2013 | 434 | 0.360 |
Why?
|
| Gastric Mucins | 3 | 1998 | 5 | 0.350 |
Why?
|
| Aging | 2 | 2015 | 1184 | 0.350 |
Why?
|
| Gastroscopy | 6 | 2013 | 102 | 0.350 |
Why?
|
| Urease | 9 | 2002 | 73 | 0.340 |
Why?
|
| Disease Progression | 10 | 2019 | 2041 | 0.340 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 94 | 0.340 |
Why?
|
| Ileum | 1 | 2010 | 132 | 0.340 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2012 | 305 | 0.330 |
Why?
|
| Gastric Fundus | 1 | 2009 | 9 | 0.330 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 225 | 0.320 |
Why?
|
| Sensitivity and Specificity | 17 | 2016 | 2031 | 0.310 |
Why?
|
| Italy | 5 | 2018 | 113 | 0.310 |
Why?
|
| Cause of Death | 1 | 2011 | 468 | 0.310 |
Why?
|
| Endoscopy | 7 | 2024 | 284 | 0.300 |
Why?
|
| Bacterial Adhesion | 3 | 1998 | 108 | 0.300 |
Why?
|
| Incidence | 8 | 2018 | 3086 | 0.300 |
Why?
|
| Pathologists | 3 | 2024 | 29 | 0.300 |
Why?
|
| Heartburn | 3 | 2023 | 15 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2012 | 619 | 0.290 |
Why?
|
| Bacterial Proteins | 10 | 2004 | 885 | 0.290 |
Why?
|
| Lymphoid Tissue | 5 | 1999 | 47 | 0.280 |
Why?
|
| Seasons | 3 | 2019 | 309 | 0.280 |
Why?
|
| Mastocytosis | 2 | 2024 | 7 | 0.280 |
Why?
|
| AIDS-Related Opportunistic Infections | 8 | 1996 | 136 | 0.280 |
Why?
|
| Autoantigens | 3 | 2004 | 119 | 0.280 |
Why?
|
| Secondary Prevention | 2 | 2019 | 215 | 0.280 |
Why?
|
| Infant, Newborn | 9 | 2020 | 8185 | 0.270 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 144 | 0.270 |
Why?
|
| Cohort Studies | 6 | 2017 | 4733 | 0.270 |
Why?
|
| Observer Variation | 6 | 2020 | 302 | 0.270 |
Why?
|
| Specimen Handling | 5 | 2016 | 140 | 0.270 |
Why?
|
| Physician's Role | 1 | 2008 | 165 | 0.260 |
Why?
|
| Intestinal Diseases, Parasitic | 5 | 1995 | 39 | 0.260 |
Why?
|
| Geography, Medical | 2 | 2017 | 16 | 0.260 |
Why?
|
| Wheat Hypersensitivity | 1 | 2005 | 3 | 0.250 |
Why?
|
| Enterochromaffin-like Cells | 2 | 2003 | 3 | 0.250 |
Why?
|
| Bismuth | 9 | 1999 | 79 | 0.240 |
Why?
|
| Dyspepsia | 5 | 2018 | 101 | 0.240 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 582 | 0.240 |
Why?
|
| Deglutition Disorders | 3 | 2023 | 130 | 0.240 |
Why?
|
| Truth Disclosure | 1 | 2006 | 103 | 0.240 |
Why?
|
| Amoxicillin | 8 | 1997 | 120 | 0.240 |
Why?
|
| Publishing | 1 | 2006 | 110 | 0.240 |
Why?
|
| Immunoglobulin E | 9 | 1989 | 162 | 0.220 |
Why?
|
| Desensitization, Immunologic | 1 | 2005 | 103 | 0.220 |
Why?
|
| Tetracycline | 7 | 1997 | 77 | 0.220 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2004 | 49 | 0.220 |
Why?
|
| Calcium-Binding Proteins | 2 | 2011 | 324 | 0.220 |
Why?
|
| Animals | 45 | 2024 | 34147 | 0.220 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2024 | 383 | 0.220 |
Why?
|
| Quinolones | 1 | 2003 | 53 | 0.210 |
Why?
|
| Esomeprazole | 1 | 2003 | 31 | 0.210 |
Why?
|
| Apoptosis | 4 | 2018 | 1790 | 0.210 |
Why?
|
| Mucous Membrane | 3 | 2011 | 88 | 0.210 |
Why?
|
| Salicylates | 7 | 1999 | 53 | 0.210 |
Why?
|
| Comorbidity | 2 | 2018 | 1514 | 0.210 |
Why?
|
| HIV Infections | 2 | 2014 | 1890 | 0.210 |
Why?
|
| Puerto Rico | 3 | 2013 | 45 | 0.210 |
Why?
|
| Alanine | 1 | 2003 | 181 | 0.210 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 48 | 0.200 |
Why?
|
| Disease Models, Animal | 14 | 2013 | 4355 | 0.200 |
Why?
|
| Drug Therapy, Combination | 18 | 2019 | 1154 | 0.200 |
Why?
|
| Organometallic Compounds | 7 | 1999 | 108 | 0.200 |
Why?
|
| Veterans | 4 | 2019 | 1752 | 0.200 |
Why?
|
| Outpatients | 2 | 2022 | 253 | 0.200 |
Why?
|
| Reagent Strips | 3 | 1997 | 11 | 0.200 |
Why?
|
| Paraffin Embedding | 2 | 2021 | 33 | 0.200 |
Why?
|
| Autoimmune Diseases | 2 | 2015 | 251 | 0.200 |
Why?
|
| Metronidazole | 8 | 1997 | 155 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 141 | 0.190 |
Why?
|
| Adipose Tissue | 1 | 2024 | 470 | 0.190 |
Why?
|
| Linear Models | 2 | 2015 | 671 | 0.190 |
Why?
|
| Breath Tests | 5 | 2002 | 179 | 0.190 |
Why?
|
| Stem Cells | 2 | 2017 | 701 | 0.190 |
Why?
|
| History, 19th Century | 3 | 2016 | 116 | 0.190 |
Why?
|
| Blood Platelets | 1 | 2004 | 325 | 0.190 |
Why?
|
| Tissue Fixation | 1 | 2021 | 38 | 0.190 |
Why?
|
| Antibodies, Helminth | 4 | 1989 | 124 | 0.180 |
Why?
|
| Ribotyping | 1 | 2021 | 50 | 0.180 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2020 | 11 | 0.180 |
Why?
|
| Cell Degranulation | 1 | 2020 | 29 | 0.180 |
Why?
|
| Lectins | 1 | 2020 | 50 | 0.180 |
Why?
|
| Biomarkers, Tumor | 5 | 2018 | 1459 | 0.180 |
Why?
|
| Graves Disease | 1 | 2020 | 16 | 0.170 |
Why?
|
| Esophageal Achalasia | 1 | 2020 | 36 | 0.170 |
Why?
|
| Esophagoscopy | 4 | 2012 | 156 | 0.170 |
Why?
|
| Surgicenters | 1 | 2020 | 4 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 1996 | 816 | 0.170 |
Why?
|
| Lymphoma | 3 | 2012 | 322 | 0.170 |
Why?
|
| Lymphocyte Activation | 5 | 1986 | 688 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 171 | 0.160 |
Why?
|
| Cryptosporidiosis | 3 | 1995 | 41 | 0.160 |
Why?
|
| Strongyloides stercoralis | 3 | 1996 | 22 | 0.160 |
Why?
|
| Time Factors | 16 | 2016 | 6273 | 0.160 |
Why?
|
| Neoplasms | 1 | 2014 | 2800 | 0.160 |
Why?
|
| Epithelium | 8 | 2012 | 361 | 0.160 |
Why?
|
| Brucellosis | 2 | 2014 | 19 | 0.160 |
Why?
|
| Goblet Cells | 1 | 2020 | 104 | 0.160 |
Why?
|
| France | 2 | 2011 | 79 | 0.160 |
Why?
|
| Dogs | 7 | 1996 | 767 | 0.160 |
Why?
|
| Gerbillinae | 6 | 2007 | 55 | 0.160 |
Why?
|
| Neutrophils | 6 | 2016 | 378 | 0.160 |
Why?
|
| Clarithromycin | 7 | 1996 | 125 | 0.160 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 1998 | 11 | 0.160 |
Why?
|
| Opportunistic Infections | 2 | 1989 | 78 | 0.160 |
Why?
|
| Lung Diseases, Parasitic | 2 | 1988 | 14 | 0.150 |
Why?
|
| Mass Screening | 2 | 2004 | 784 | 0.150 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 1998 | 20 | 0.150 |
Why?
|
| In Situ Hybridization | 5 | 1996 | 470 | 0.150 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1998 | 37 | 0.150 |
Why?
|
| Microvilli | 2 | 2017 | 72 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 786 | 0.150 |
Why?
|
| Intestinal Diseases | 2 | 2015 | 84 | 0.150 |
Why?
|
| Reproducibility of Results | 8 | 2014 | 2875 | 0.150 |
Why?
|
| Gene Expression | 3 | 2020 | 1569 | 0.150 |
Why?
|
| Intestinal Polyps | 3 | 2011 | 29 | 0.150 |
Why?
|
| Glutarates | 1 | 2018 | 37 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 606 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 227 | 0.140 |
Why?
|
| Prescriptions | 1 | 2017 | 40 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 1114 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 3 | 1996 | 218 | 0.140 |
Why?
|
| Diagnostic Errors | 2 | 2012 | 332 | 0.140 |
Why?
|
| Urea | 5 | 2002 | 226 | 0.140 |
Why?
|
| Tetrazoles | 1 | 2017 | 63 | 0.140 |
Why?
|
| Bile Acids and Salts | 2 | 2010 | 245 | 0.140 |
Why?
|
| Colony Count, Microbial | 3 | 1996 | 89 | 0.140 |
Why?
|
| Giardiasis | 1 | 2017 | 10 | 0.140 |
Why?
|
| False Negative Reactions | 7 | 2010 | 89 | 0.140 |
Why?
|
| Filariasis | 2 | 1988 | 27 | 0.130 |
Why?
|
| HIV Seropositivity | 2 | 2014 | 119 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 504 | 0.130 |
Why?
|
| Imidazoles | 1 | 2017 | 194 | 0.130 |
Why?
|
| Dog Diseases | 2 | 1988 | 49 | 0.130 |
Why?
|
| Texas | 3 | 2016 | 3591 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 1 | 1999 | 671 | 0.130 |
Why?
|
| Consensus | 4 | 2022 | 629 | 0.130 |
Why?
|
| Herpes Genitalis | 1 | 1996 | 11 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 5 | 2000 | 260 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 870 | 0.130 |
Why?
|
| Environment | 1 | 2017 | 145 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2016 | 97 | 0.130 |
Why?
|
| Jews | 1 | 2015 | 32 | 0.130 |
Why?
|
| Educational Status | 1 | 2017 | 272 | 0.130 |
Why?
|
| Indians, North American | 1 | 2015 | 59 | 0.130 |
Why?
|
| History, 18th Century | 2 | 2016 | 70 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 656 | 0.120 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 402 | 0.120 |
Why?
|
| Risk | 2 | 2018 | 749 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 1996 | 235 | 0.120 |
Why?
|
| Cell Count | 3 | 2023 | 252 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 2016 | 224 | 0.120 |
Why?
|
| Coinfection | 1 | 2017 | 171 | 0.120 |
Why?
|
| Liver Diseases | 3 | 2014 | 366 | 0.120 |
Why?
|
| Cells, Cultured | 6 | 2024 | 3052 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2014 | 230 | 0.120 |
Why?
|
| Antigens, Helminth | 5 | 1994 | 190 | 0.120 |
Why?
|
| Immune Tolerance | 4 | 1989 | 145 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 398 | 0.120 |
Why?
|
| Jejunum | 2 | 2013 | 128 | 0.110 |
Why?
|
| Phenotype | 8 | 2018 | 4256 | 0.110 |
Why?
|
| Population Density | 1 | 2014 | 34 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 244 | 0.110 |
Why?
|
| Urethral Neoplasms | 1 | 1994 | 9 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2012 | 719 | 0.110 |
Why?
|
| Rural Health | 1 | 2014 | 48 | 0.110 |
Why?
|
| Urban Health | 1 | 2014 | 74 | 0.110 |
Why?
|
| Epidemiologic Studies | 1 | 2014 | 43 | 0.110 |
Why?
|
| Penile Neoplasms | 1 | 1994 | 32 | 0.110 |
Why?
|
| DNA, Bacterial | 7 | 2002 | 475 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 8 | 2002 | 1584 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 65 | 0.110 |
Why?
|
| Urinary Bladder Fistula | 1 | 1993 | 4 | 0.110 |
Why?
|
| Algorithms | 2 | 2014 | 1612 | 0.110 |
Why?
|
| Pouchitis | 1 | 2013 | 3 | 0.110 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2013 | 7 | 0.110 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 49 | 0.110 |
Why?
|
| Japan | 2 | 2006 | 133 | 0.110 |
Why?
|
| Obesity | 1 | 2024 | 2251 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2012 | 775 | 0.110 |
Why?
|
| Intestinal Fistula | 1 | 1993 | 28 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1994 | 71 | 0.110 |
Why?
|
| Statistics, Nonparametric | 3 | 2011 | 426 | 0.100 |
Why?
|
| Superinfection | 1 | 1992 | 6 | 0.100 |
Why?
|
| Larva | 8 | 1996 | 248 | 0.100 |
Why?
|
| Intestinal Perforation | 1 | 1993 | 60 | 0.100 |
Why?
|
| Colon, Descending | 1 | 2012 | 3 | 0.100 |
Why?
|
| Colon, Ascending | 1 | 2012 | 8 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 2 | 2009 | 121 | 0.100 |
Why?
|
| Ulcer | 1 | 1992 | 48 | 0.100 |
Why?
|
| Education, Medical, Continuing | 2 | 2010 | 138 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1994 | 193 | 0.100 |
Why?
|
| Reference Values | 3 | 2007 | 709 | 0.100 |
Why?
|
| Climate | 1 | 2012 | 20 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2012 | 48 | 0.100 |
Why?
|
| Helminthiasis | 1 | 1993 | 76 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 295 | 0.100 |
Why?
|
| Penicillins | 3 | 1997 | 154 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 266 | 0.100 |
Why?
|
| Inflammation | 5 | 2022 | 1414 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 67 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 162 | 0.100 |
Why?
|
| Biomarkers | 4 | 2016 | 2980 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1272 | 0.090 |
Why?
|
| Cell Division | 3 | 2003 | 781 | 0.090 |
Why?
|
| Mesenteric Veins | 1 | 1991 | 15 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 66 | 0.090 |
Why?
|
| Food Preservation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Chlorogenic Acid | 1 | 2011 | 1 | 0.090 |
Why?
|
| Diet | 2 | 2011 | 1131 | 0.090 |
Why?
|
| Tannins | 1 | 2011 | 2 | 0.090 |
Why?
|
| Necatoriasis | 1 | 1991 | 37 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 411 | 0.090 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2011 | 27 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 720 | 0.090 |
Why?
|
| Genes, APC | 1 | 2010 | 13 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1996 | 449 | 0.090 |
Why?
|
| Phenols | 1 | 2011 | 55 | 0.090 |
Why?
|
| Anemia | 1 | 2014 | 341 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 692 | 0.090 |
Why?
|
| Serologic Tests | 2 | 1988 | 118 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 169 | 0.090 |
Why?
|
| Flavonoids | 1 | 2011 | 78 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2013 | 389 | 0.090 |
Why?
|
| Public Health | 1 | 2012 | 260 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 221 | 0.090 |
Why?
|
| Homeodomain Proteins | 2 | 2011 | 546 | 0.090 |
Why?
|
| Epithelial Cells | 3 | 2010 | 911 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1992 | 316 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 281 | 0.090 |
Why?
|
| Immunoglobulin A | 2 | 1988 | 207 | 0.080 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 79 | 0.080 |
Why?
|
| Oklahoma | 1 | 2009 | 8 | 0.080 |
Why?
|
| Coloring Agents | 4 | 2006 | 79 | 0.080 |
Why?
|
| Esophageal Stenosis | 1 | 2009 | 44 | 0.080 |
Why?
|
| District of Columbia | 1 | 2009 | 16 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 380 | 0.080 |
Why?
|
| Cytokines | 3 | 2011 | 1279 | 0.080 |
Why?
|
| Hepatitis C | 2 | 2004 | 364 | 0.080 |
Why?
|
| International Cooperation | 2 | 2021 | 157 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 206 | 0.080 |
Why?
|
| Nematode Infections | 1 | 1988 | 6 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2009 | 677 | 0.080 |
Why?
|
| Skin | 3 | 1996 | 510 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 1598 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 1999 | 39 | 0.080 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2008 | 28 | 0.080 |
Why?
|
| JC Virus | 1 | 2008 | 29 | 0.080 |
Why?
|
| Feces | 6 | 1996 | 717 | 0.070 |
Why?
|
| Ischemia | 1 | 1991 | 354 | 0.070 |
Why?
|
| Lung | 5 | 1989 | 1483 | 0.070 |
Why?
|
| DNA Fingerprinting | 3 | 2002 | 107 | 0.070 |
Why?
|
| RNA, Messenger | 5 | 2010 | 2824 | 0.070 |
Why?
|
| Erythrocebus patas | 2 | 1984 | 4 | 0.070 |
Why?
|
| Cercopithecidae | 2 | 1984 | 7 | 0.070 |
Why?
|
| Microscopy, Electron | 5 | 2006 | 395 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 2008 | 133 | 0.070 |
Why?
|
| Polyomavirus Infections | 1 | 2008 | 90 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2012 | 820 | 0.070 |
Why?
|
| Switzerland | 1 | 2007 | 16 | 0.070 |
Why?
|
| Health Services Research | 1 | 2009 | 187 | 0.070 |
Why?
|
| Ranitidine | 6 | 1996 | 30 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 1404 | 0.070 |
Why?
|
| Cat Diseases | 2 | 1997 | 14 | 0.070 |
Why?
|
| Warfare | 1 | 1987 | 35 | 0.070 |
Why?
|
| Calcinosis | 1 | 1988 | 174 | 0.070 |
Why?
|
| Antibody Specificity | 5 | 1988 | 202 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 675 | 0.070 |
Why?
|
| Immunoglobulins | 2 | 1984 | 170 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 1994 | 803 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 389 | 0.070 |
Why?
|
| Cross Reactions | 2 | 2004 | 193 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2003 | 1086 | 0.070 |
Why?
|
| Esophagoscopes | 1 | 2006 | 4 | 0.070 |
Why?
|
| Vasculitis | 1 | 2006 | 49 | 0.070 |
Why?
|
| Neuroglia | 1 | 2008 | 201 | 0.070 |
Why?
|
| Myxoma | 1 | 2006 | 29 | 0.070 |
Why?
|
| Myenteric Plexus | 2 | 2020 | 12 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2006 | 36 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 5 | 1996 | 256 | 0.060 |
Why?
|
| Antibodies | 2 | 1989 | 371 | 0.060 |
Why?
|
| Smoking | 1 | 2011 | 1037 | 0.060 |
Why?
|
| Caco-2 Cells | 2 | 2018 | 95 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 4 | 1998 | 1015 | 0.060 |
Why?
|
| Heart Neoplasms | 1 | 2006 | 102 | 0.060 |
Why?
|
| Europe | 2 | 2000 | 352 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2013 | 12289 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 281 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2024 | 80 | 0.060 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2024 | 67 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 483 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 1994 | 1531 | 0.060 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2004 | 9 | 0.060 |
Why?
|
| Microsporidiosis | 2 | 1995 | 6 | 0.060 |
Why?
|
| Monocytes | 2 | 1999 | 352 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 685 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 1688 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 5 | 2013 | 4425 | 0.060 |
Why?
|
| Carcinoma | 3 | 2010 | 280 | 0.060 |
Why?
|
| Lithostathine | 1 | 2003 | 2 | 0.060 |
Why?
|
| Gastric Acidity Determination | 1 | 2003 | 19 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2010 | 1004 | 0.060 |
Why?
|
| Hepatitis B virus | 2 | 1996 | 136 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2006 | 300 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2017 | 229 | 0.060 |
Why?
|
| Cytomegalovirus | 3 | 1996 | 270 | 0.050 |
Why?
|
| Models, Biological | 2 | 2003 | 1459 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2004 | 180 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 87 | 0.050 |
Why?
|
| Mice | 8 | 2018 | 17729 | 0.050 |
Why?
|
| Fundoplication | 2 | 2019 | 66 | 0.050 |
Why?
|
| Brazil | 2 | 2018 | 123 | 0.050 |
Why?
|
| Comprehension | 1 | 2023 | 75 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 263 | 0.050 |
Why?
|
| Immunity, Cellular | 3 | 1992 | 202 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 228 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2000 | 1064 | 0.050 |
Why?
|
| Thymidine Phosphorylase | 1 | 2002 | 12 | 0.050 |
Why?
|
| Base Sequence | 3 | 2003 | 3094 | 0.050 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Chest Pain | 1 | 2023 | 124 | 0.050 |
Why?
|
| Prednisolone | 3 | 1989 | 74 | 0.050 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2002 | 37 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2003 | 625 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1482 | 0.050 |
Why?
|
| DNA, Viral | 3 | 2008 | 479 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 1982 | 121 | 0.050 |
Why?
|
| Rats | 5 | 2009 | 3687 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 72 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 142 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2024 | 334 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2002 | 64 | 0.050 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2002 | 58 | 0.050 |
Why?
|
| Fixatives | 1 | 2021 | 14 | 0.050 |
Why?
|
| Forecasting | 3 | 1997 | 351 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2021 | 34 | 0.050 |
Why?
|
| Methylnitrosourea | 1 | 2001 | 19 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1619 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 150 | 0.050 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2020 | 16 | 0.050 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2000 | 7 | 0.050 |
Why?
|
| Trefoil Factor-2 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2003 | 862 | 0.040 |
Why?
|
| Host-Parasite Interactions | 2 | 1992 | 70 | 0.040 |
Why?
|
| Lipid Peroxidation | 2 | 2011 | 88 | 0.040 |
Why?
|
| Quality of Life | 2 | 2021 | 1954 | 0.040 |
Why?
|
| Receptors, Thyrotropin | 1 | 2020 | 11 | 0.040 |
Why?
|
| Agar | 2 | 1997 | 16 | 0.040 |
Why?
|
| Hot Temperature | 2 | 1996 | 136 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 3873 | 0.040 |
Why?
|
| Desipramine | 1 | 2019 | 27 | 0.040 |
Why?
|
| Antitrichomonal Agents | 2 | 1997 | 10 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2006 | 1039 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2000 | 77 | 0.040 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2016 | 27 | 0.040 |
Why?
|
| Muscle Relaxants, Central | 1 | 2019 | 33 | 0.040 |
Why?
|
| Histocytological Preparation Techniques | 1 | 1999 | 5 | 0.040 |
Why?
|
| Baclofen | 1 | 2019 | 39 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 403 | 0.040 |
Why?
|
| Liver Function Tests | 2 | 2014 | 101 | 0.040 |
Why?
|
| Family | 1 | 2002 | 566 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 1999 | 16 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 223 | 0.040 |
Why?
|
| Autopsy | 2 | 2016 | 111 | 0.040 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 1999 | 8 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2000 | 356 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 548 | 0.040 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1998 | 12 | 0.040 |
Why?
|
| CA-19-9 Antigen | 1 | 1998 | 10 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 1999 | 55 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 256 | 0.040 |
Why?
|
| Fiber Optic Technology | 1 | 1999 | 46 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2304 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 1998 | 33 | 0.040 |
Why?
|
| Immunoblotting | 2 | 1989 | 313 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 421 | 0.040 |
Why?
|
| Glycosylation | 1 | 1998 | 119 | 0.040 |
Why?
|
| Cell Line | 3 | 2013 | 2771 | 0.040 |
Why?
|
| Korea | 1 | 1998 | 35 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 363 | 0.040 |
Why?
|
| Bacteriological Techniques | 2 | 1995 | 86 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1989 | 314 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 1998 | 65 | 0.040 |
Why?
|
| Airway Remodeling | 1 | 2018 | 21 | 0.040 |
Why?
|
| Azoxymethane | 1 | 2018 | 11 | 0.040 |
Why?
|
| Adenoma, Villous | 1 | 2017 | 2 | 0.040 |
Why?
|
| Bronchi | 1 | 1998 | 98 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 48 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 98 | 0.040 |
Why?
|
| Furazolidone | 1 | 1997 | 8 | 0.040 |
Why?
|
| Remission Induction | 2 | 2013 | 301 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2024 | 4535 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 1341 | 0.030 |
Why?
|
| Acute Disease | 3 | 2014 | 1101 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2017 | 37 | 0.030 |
Why?
|
| Vietnam | 2 | 1987 | 45 | 0.030 |
Why?
|
| Clinical Enzyme Tests | 1 | 1996 | 14 | 0.030 |
Why?
|
| Drug Administration Schedule | 5 | 1996 | 725 | 0.030 |
Why?
|
| HIV Enteropathy | 1 | 1996 | 2 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2007 | 2608 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2013 | 1625 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 1998 | 320 | 0.030 |
Why?
|
| False Positive Reactions | 4 | 1997 | 144 | 0.030 |
Why?
|
| Pain Measurement | 1 | 1998 | 360 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2010 | 459 | 0.030 |
Why?
|
| Herpesvirus 2, Human | 1 | 1996 | 13 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 432 | 0.030 |
Why?
|
| Epidemiologic Factors | 1 | 1995 | 8 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2016 | 68 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 1995 | 16 | 0.030 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 1995 | 9 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 2408 | 0.030 |
Why?
|
| Audiovisual Aids | 1 | 1996 | 25 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 806 | 0.030 |
Why?
|
| Fetal Death | 1 | 1996 | 112 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1998 | 525 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 226 | 0.030 |
Why?
|
| Virus Replication | 2 | 1996 | 610 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 348 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 3735 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2002 | 834 | 0.030 |
Why?
|
| Sodium Bicarbonate | 1 | 1995 | 52 | 0.030 |
Why?
|
| Fasting | 1 | 1996 | 300 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 3137 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2011 | 1003 | 0.030 |
Why?
|
| Azithromycin | 1 | 1995 | 44 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2007 | 1702 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 1994 | 437 | 0.030 |
Why?
|
| Brucella melitensis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2015 | 172 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 257 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 1099 | 0.030 |
Why?
|
| Pregnancy | 2 | 1998 | 7167 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 1998 | 447 | 0.030 |
Why?
|
| Cell Movement | 1 | 2018 | 835 | 0.030 |
Why?
|
| Hepatovirus | 1 | 1994 | 17 | 0.030 |
Why?
|
| Parasite Egg Count | 2 | 1995 | 28 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2014 | 41 | 0.030 |
Why?
|
| Gallbladder | 1 | 1994 | 20 | 0.030 |
Why?
|
| Cholecystitis | 1 | 1994 | 20 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 1994 | 58 | 0.030 |
Why?
|
| Complement Activation | 1 | 1994 | 52 | 0.030 |
Why?
|
| Microsporida | 1 | 1993 | 2 | 0.030 |
Why?
|
| Keratin-18 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Keratin-14 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Hepatitis B Antigens | 1 | 1993 | 10 | 0.030 |
Why?
|
| Keratin-8 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Achlorhydria | 1 | 1993 | 6 | 0.030 |
Why?
|
| Carbon Isotopes | 3 | 2002 | 276 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 2013 | 17 | 0.030 |
Why?
|
| Bile Ducts | 1 | 1994 | 55 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2013 | 27 | 0.030 |
Why?
|
| Urethra | 1 | 1994 | 84 | 0.030 |
Why?
|
| New York | 1 | 2013 | 68 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 578 | 0.030 |
Why?
|
| Homosexuality | 1 | 1993 | 18 | 0.030 |
Why?
|
| Body Weight | 2 | 1988 | 1005 | 0.030 |
Why?
|
| Dental Plaque | 1 | 1993 | 5 | 0.030 |
Why?
|
| Penis | 1 | 1994 | 97 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 39 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 683 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 168 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 80 | 0.030 |
Why?
|
| Cryptosporidium | 1 | 1993 | 31 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 150 | 0.030 |
Why?
|
| Liver | 3 | 1996 | 1761 | 0.030 |
Why?
|
| Intestinal Absorption | 2 | 1995 | 190 | 0.030 |
Why?
|
| Helminths | 1 | 1993 | 46 | 0.030 |
Why?
|
| Indoles | 1 | 2013 | 181 | 0.030 |
Why?
|
| Patient Compliance | 2 | 1995 | 473 | 0.030 |
Why?
|
| Workload | 1 | 2013 | 148 | 0.020 |
Why?
|
| Hepatitis B | 1 | 1993 | 160 | 0.020 |
Why?
|
| Hoarseness | 1 | 2012 | 11 | 0.020 |
Why?
|
| Transcription Factor HES-1 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 179 | 0.020 |
Why?
|
| Probability | 2 | 2004 | 323 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2011 | 38 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 54 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1993 | 327 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 316 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2011 | 53 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1991 | 20 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2012 | 69 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 510 | 0.020 |
Why?
|
| Polyphenols | 1 | 2011 | 19 | 0.020 |
Why?
|
| Prostate | 1 | 1994 | 431 | 0.020 |
Why?
|
| Drinking | 1 | 2011 | 34 | 0.020 |
Why?
|
| Genotype | 2 | 2010 | 2552 | 0.020 |
Why?
|
| Cough | 1 | 2012 | 88 | 0.020 |
Why?
|
| Macaca | 1 | 2011 | 61 | 0.020 |
Why?
|
| Pneumonia, Viral | 1 | 1996 | 374 | 0.020 |
Why?
|
| DNA | 1 | 1996 | 1599 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2010 | 136 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2010 | 8 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2010 | 106 | 0.020 |
Why?
|
| Refugees | 1 | 1990 | 30 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 117 | 0.020 |
Why?
|
| Duodenostomy | 1 | 2009 | 1 | 0.020 |
Why?
|
| Esophagostomy | 1 | 2009 | 2 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1995 | 988 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 157 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 61 | 0.020 |
Why?
|
| Latin America | 1 | 1989 | 88 | 0.020 |
Why?
|
| Asia | 1 | 1989 | 107 | 0.020 |
Why?
|
| Africa | 1 | 1989 | 132 | 0.020 |
Why?
|
| Gastrointestinal Agents | 1 | 2009 | 60 | 0.020 |
Why?
|
| Strongyloidea | 1 | 1988 | 1 | 0.020 |
Why?
|
| Sucrase | 1 | 1988 | 23 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 359 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 233 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 503 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 12 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 1988 | 145 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1988 | 98 | 0.020 |
Why?
|
| Carbon Dioxide | 2 | 2002 | 273 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1988 | 90 | 0.020 |
Why?
|
| Manometry | 1 | 2008 | 48 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 1968 | 81 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 288 | 0.020 |
Why?
|
| Thailand | 1 | 1987 | 37 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1993 | 459 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1987 | 110 | 0.020 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2007 | 8 | 0.020 |
Why?
|
| E2F Transcription Factors | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cats | 2 | 1997 | 116 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 41 | 0.020 |
Why?
|
| Immunoassay | 1 | 1987 | 128 | 0.020 |
Why?
|
| Interferon Regulatory Factors | 1 | 2007 | 38 | 0.020 |
Why?
|
| Basophils | 2 | 1984 | 11 | 0.020 |
Why?
|
| Radioallergosorbent Test | 1 | 1986 | 7 | 0.020 |
Why?
|
| Prednisone | 2 | 1984 | 274 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 106 | 0.020 |
Why?
|
| Morbidity | 1 | 2007 | 244 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 109 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 101 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 107 | 0.020 |
Why?
|
| Digestive System | 1 | 1986 | 59 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 1996 | 53 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1228 | 0.020 |
Why?
|
| Methylene Blue | 1 | 2006 | 13 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2006 | 108 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 206 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 1997 | 215 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2005 | 70 | 0.020 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2006 | 64 | 0.020 |
Why?
|
| Spleen | 2 | 1984 | 280 | 0.020 |
Why?
|
| Microscopy | 1 | 2006 | 117 | 0.020 |
Why?
|
| Intracranial Aneurysm | 1 | 1986 | 93 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1986 | 211 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 348 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1984 | 10 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 237 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 204 | 0.010 |
Why?
|
| Iodide Peroxidase | 1 | 2004 | 8 | 0.010 |
Why?
|
| Haplorhini | 1 | 1984 | 123 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 3342 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2004 | 24 | 0.010 |
Why?
|
| Iron-Binding Proteins | 1 | 2004 | 32 | 0.010 |
Why?
|
| Treatment Failure | 2 | 1995 | 342 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 1984 | 376 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1674 | 0.010 |
Why?
|
| Asthma | 1 | 2012 | 748 | 0.010 |
Why?
|
| Skin Tests | 1 | 1984 | 74 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1899 | 0.010 |
Why?
|
| Genomic Instability | 1 | 2005 | 229 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 342 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1529 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1930 | 0.010 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 23 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1983 | 12 | 0.010 |
Why?
|
| Tuberculin | 1 | 1983 | 8 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1984 | 262 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2003 | 40 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 1983 | 45 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 1015 | 0.010 |
Why?
|
| Histamine Release | 1 | 1983 | 10 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 426 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1288 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 515 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1983 | 68 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 159 | 0.010 |
Why?
|
| Antigens | 1 | 1983 | 156 | 0.010 |
Why?
|
| Thiabendazole | 1 | 1982 | 2 | 0.010 |
Why?
|
| Global Health | 1 | 2007 | 558 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 151 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 582 | 0.010 |
Why?
|
| Proton Pumps | 1 | 2002 | 11 | 0.010 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2002 | 107 | 0.010 |
Why?
|
| Virulence | 1 | 2002 | 262 | 0.010 |
Why?
|
| Physicians | 1 | 1968 | 579 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 669 | 0.010 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2002 | 95 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 240 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 2 | 1993 | 328 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2002 | 369 | 0.010 |
Why?
|
| Respiration | 1 | 2002 | 121 | 0.010 |
Why?
|
| Arteries | 1 | 2002 | 220 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2535 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 265 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2000 | 113 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1999 | 30 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1999 | 118 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1999 | 26 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2000 | 219 | 0.010 |
Why?
|
| CD18 Antigens | 1 | 1999 | 49 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2000 | 144 | 0.010 |
Why?
|
| Colonoscopes | 1 | 1999 | 9 | 0.010 |
Why?
|
| Equipment Safety | 1 | 1999 | 36 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1999 | 90 | 0.010 |
Why?
|
| Species Specificity | 1 | 1999 | 548 | 0.010 |
Why?
|
| Azure Stains | 1 | 1998 | 4 | 0.010 |
Why?
|
| Medical Laboratory Personnel | 1 | 1998 | 9 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1998 | 21 | 0.010 |
Why?
|
| Medical Laboratory Science | 1 | 1998 | 13 | 0.010 |
Why?
|
| Chaperonin 60 | 1 | 1997 | 32 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1997 | 75 | 0.010 |
Why?
|
| Pentagastrin | 1 | 1997 | 6 | 0.010 |
Why?
|
| Antacids | 1 | 1997 | 26 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2000 | 455 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1997 | 53 | 0.010 |
Why?
|
| Zoonoses | 1 | 1997 | 44 | 0.010 |
Why?
|
| Oviposition | 1 | 1996 | 6 | 0.010 |
Why?
|
| Lansoprazole | 1 | 1996 | 22 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1998 | 141 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1997 | 192 | 0.010 |
Why?
|
| Adhesins, Bacterial | 1 | 1997 | 75 | 0.010 |
Why?
|
| Equipment Design | 1 | 1999 | 597 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1997 | 279 | 0.010 |
Why?
|
| DNA Probes | 1 | 1996 | 124 | 0.010 |
Why?
|
| Gels | 1 | 1996 | 68 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1996 | 37 | 0.010 |
Why?
|
| Parasites | 1 | 1996 | 31 | 0.010 |
Why?
|
| Arthritis | 1 | 1996 | 81 | 0.010 |
Why?
|
| Fungi | 1 | 1996 | 69 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 151 | 0.010 |
Why?
|
| Enterovirus | 1 | 1996 | 52 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1996 | 237 | 0.010 |
Why?
|
| India | 1 | 1996 | 219 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1996 | 426 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 1997 | 370 | 0.010 |
Why?
|
| Adhesins, Escherichia coli | 1 | 1995 | 20 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1996 | 153 | 0.010 |
Why?
|
| Research | 1 | 1997 | 263 | 0.010 |
Why?
|
| Xylose | 1 | 1995 | 9 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1996 | 301 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 1996 | 136 | 0.010 |
Why?
|
| Lactulose | 1 | 1995 | 39 | 0.010 |
Why?
|
| Mannitol | 1 | 1995 | 49 | 0.010 |
Why?
|
| Vitamin B 12 | 1 | 1995 | 55 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1995 | 83 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 1006 | 0.010 |
Why?
|
| Random Allocation | 1 | 1995 | 436 | 0.010 |
Why?
|
| Immunoelectrophoresis | 1 | 1994 | 12 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1994 | 23 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1994 | 25 | 0.010 |
Why?
|
| ROC Curve | 1 | 1996 | 562 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1995 | 395 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1994 | 105 | 0.010 |
Why?
|
| Gastric Juice | 1 | 1993 | 13 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1993 | 56 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 223 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1996 | 539 | 0.010 |
Why?
|
| Body Water | 1 | 1993 | 90 | 0.010 |
Why?
|
| Hepatoblastoma | 1 | 1996 | 180 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1996 | 616 | 0.010 |
Why?
|
| Paromomycin | 1 | 1993 | 3 | 0.010 |
Why?
|
| Ammonia | 1 | 1993 | 74 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1994 | 319 | 0.010 |
Why?
|
| Food | 1 | 1993 | 125 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1993 | 150 | 0.010 |
Why?
|
| Immunochemistry | 1 | 1991 | 30 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1993 | 355 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 1996 | 746 | 0.010 |
Why?
|
| Asia, Southeastern | 1 | 1990 | 20 | 0.010 |
Why?
|
| Canada | 1 | 1990 | 299 | 0.010 |
Why?
|
| Sweden | 1 | 1968 | 35 | 0.000 |
Why?
|
| Foreign Medical Graduates | 1 | 1968 | 12 | 0.000 |
Why?
|
| Medullary Sponge Kidney | 1 | 1986 | 2 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1995 | 938 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 1318 | 0.000 |
Why?
|